{"id":"W2111404068","doi":"10.1016/s1470-2045(14)70012-9","title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":978,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Medical Research Council; National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; F. Hoffmann-La Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Population; Oncology; Progression-free survival; Metastatic melanoma; Chemotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003949154,0.001826263,0.003658735,0.0004176501,0.0004627716,0.001810358,0.001102231,0.002035602,0.003582321],"category_scores_gemma":[0.002927694,0.0008570632,0.003841465,0.0004780108,0.001255677,0.002123655,0.0004808018,0.004416535,0.001153335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001321256,"about_ca_system_score_gemma":0.0009583288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009440455,"about_ca_topic_score_gemma":0.001521477,"domain_scores_codex":[0.9987283,0.0006131897,0.00006362491,0.0001620243,0.0001274831,0.0003054112],"domain_scores_gemma":[0.9979856,0.0005695259,0.0004997528,0.0002264808,0.0001319271,0.0005866196],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9567642,0.003857563,0.002038258,0.0004802949,0.001854866,0.00007925976,0.00008827834,0.0008627842,0.005060294,0.00008658344,0.001124001,0.02770358],"study_design_scores_gemma":[0.8063305,0.1664794,0.0206879,0.00007640621,0.001679424,0.0002263101,0.0000783322,0.0009554772,0.001380702,0.0004578911,0.001575633,0.00007200619],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916729,0.004752457,0.0004626338,0.0004093361,0.0001912818,0.0004646235,0.000985936,0.00008585576,0.0009748869],"genre_scores_gemma":[0.9937229,0.001502167,0.0004907216,0.000620322,0.0002330184,0.0006096335,0.001358075,0.00003562452,0.001427588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003949154,"threshold_uncertainty_score":0.02088535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0286159142605539,"score_gpt":0.3339014764236995,"score_spread":0.3052855621631456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}